cimb-logo

Journal Browser

Journal Browser

Advanced Research in Glioblastoma and Neuroblastoma

A special issue of Current Issues in Molecular Biology (ISSN 1467-3045). This special issue belongs to the section "Molecular Medicine".

Deadline for manuscript submissions: 30 June 2025 | Viewed by 325

Special Issue Editor

Special Issue Information

Dear Colleagues,

Glioblastoma and neuroblastoma represent significant challenges in oncology, given their aggressive nature and limited treatment strategies. Advances in molecular research have paved the way for neuropharmaceutical innovations aimed at addressing the underlying mechanisms of these complex tumors.

Recent breakthroughs in glioblastoma and neuroblastoma research highlight the importance of molecular approaches, including drug design, computational modeling, and high-throughput screening techniques. These advancements are essential for identifying novel therapeutic targets and developing effective treatments. Additionally, overcoming the blood–brain barrier to ensure precise drug delivery to tumor sites and identifying biomarkers to monitor therapeutic efficacy are critical areas of investigation.

Translational research, which bridges molecular discoveries and clinical applications, holds promise for improving outcomes in these cancers. This Special Issue welcomes contributions that delve into various aspects of neuropharmaceutical research related to glioblastoma and neuroblastoma treatments, including original studies, comprehensive reviews, and perspective articles. By fostering collaboration and sharing insights, we aim to drive progress in therapeutic strategies for these complex diseases.

This Special Issue was co-led by the journal’s Topical Advisory Panel (TAP) member Dr. Fabrizio De Luca and the Special Issue Assistant Dr. Ludovica Gaiaschi, who contributed to and supported the collaboration and promotion process and the operation and development of this Special Issue.

Dr. Maria G. Bottone
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Issues in Molecular Biology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • glioblastoma
  • neuroblastoma
  • neuropharmaceuticals
  • drug design
  • blood–brain barrier
  • molecular therapeutics
  • brain-tumor biomarkers

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

15 pages, 21172 KiB  
Article
Antineoplastic Activity of Methyl rosmarinate in Glioblastoma Cells
by Maria Vasiliki Benekou, Panagiota Tzitiridou, Theodora Papagrigoriou, Vasiliki Galani, Chrissa Sioka, Athanassios P. Kyritsis, Diamanto Lazari and George A. Alexiou
Curr. Issues Mol. Biol. 2025, 47(3), 180; https://doi.org/10.3390/cimb47030180 - 10 Mar 2025
Viewed by 209
Abstract
Glioblastoma (GMB) is a remarkably aggressive brain malignancy characterized by high mortality rates, despite continuous advances in therapeutic approaches. Compounds derived from plants are being studied for their potent medicinal properties in the quest for more efficient therapies. This study investigated the anti-glioma [...] Read more.
Glioblastoma (GMB) is a remarkably aggressive brain malignancy characterized by high mortality rates, despite continuous advances in therapeutic approaches. Compounds derived from plants are being studied for their potent medicinal properties in the quest for more efficient therapies. This study investigated the anti-glioma properties of Methyl rosmarinate, a hydroxycinnamic acid isolated from Thymus thracicus Velen, which has previously demonstrated anti-cancer activity in various cell lines. Human glioblastoma cell lines U87 and T98 were treated with Methyl rosmarinate to assess its effect on cell viability, cell cycle distribution and migratory capacity using Trypan blue assay, flow cytometry and scratch wound healing assay, respectively. The combinatorial effects of Methyl rosmarinate and temozolomide were also analyzed with CompoSyn software. According to the outcomes, Methyl rosmarinate significantly reduced cell viability, induced cell death by interfering in cell cycle checkpoints, and inhibited migration in both GMB cell lines. Notably, in U87 cells, the compound showed a synergistic impact with temozolomide, whereas in T98 cells, there was an antagonistic relationship. These results suggest that Methyl rosmarinate has potential anti-glioma properties; however, more in vivo research is needed. Full article
(This article belongs to the Special Issue Advanced Research in Glioblastoma and Neuroblastoma)
Show Figures

Figure 1

Back to TopTop